Clin2
NCT07074756Likely a fitRecruiting

Home-based treatment support for people with glioma

GliomaRecurrent GliomaRecurrent Glioblastoma

Treatments studied

Part of Cancer clinical trials.

This study tests a digital platform that helps you manage your glioma treatment at home. It aims to make it easier to follow your treatment plan and stay connected with your care team.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
202 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have a glioma and plan to receive systemic therapy (like chemotherapy or targeted drugs) for at least 6 months.
  • You are able to care for yourself and are not bedridden (ECOG 0-2 or Karnofsky 60 or higher).
  • Your doctor expects you to live at least 6 more months.
  • You can attend study visits and complete questionnaires, possibly with help.
  • If you are able to become pregnant, you must have a negative pregnancy test before starting (unless already on treatment).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06558214Recruiting· Phase 2
Laser surgery, Optune device, and Keytruda for recurrent glioblastoma

This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.

Gainesville, Florida
NCT05540275Not yet recruiting· Phase 2
Immunotherapy plus low-dose Avastin for return glioblastoma

This Phase 2 study tests tislelizumab (an anti–PD-1 immune therapy) combined with low-dose bevacizumab (Avastin) for recurrent glioblastoma that has already been treated with bevacizumab. If you qualify, you may be offered a new combination approach aimed at slowing tumor growth.

Zhengzhou, Henan
NCT07678684Recruiting· Phase 2
Study of HF1K16 plus bevacizumab for recurrent glioma

This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.

Shanghai, Shanghai Municipality
NCT06160206Recruiting· Phase 2
Study of retifanlimab, bevacizumab, and radiation for recurrent glioblastoma

This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.

Scottsdale, Arizona
NCT05958472Not yet recruiting
Study process help for adults with glioma

This trial looks at how to help people with glioma follow the clinical research process—like visits, tests, and treatment schedules. It’s mainly for adults who can safely take part and give consent.

San Francisco, California
NCT06496971Recruiting· Phase 3
Testing focused ultrasound plus Avastin for recurrent glioblastoma

This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.

Taipei

Hear when a new Glioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.